Bio-Techne Adds Proxy Detail as Merck KGaA Vote Nears

Bio-Techne (TECH) voluntarily supplemented its merger proxy disclosures — including added detail on talks with Merck KGaA and Goldman Sachs' valuation analyses — after receiving a merger lawsuit and shareholder demand letters ahead of a key shareholder vote.

Bio-Techne (NASDAQ: TECH) has taken the route most targets take when a merger vote draws legal fire: it filed additional proxy disclosure rather than fight over whether the original document said enough. The company said it received a lawsuit tied to the proposed merger, along with shareholder demand letters, and has voluntarily supplemented the disclosures it put in front of investors ahead of the vote on its proposed combination with Merck KGaA.

The supplemental material, as reported by GuruFocus, fills in detail on two areas that almost always attract complaints in deal litigation: the sequence of talks between Bio-Techne and Merck KGaA, and the valuation analyses prepared by Goldman Sachs, the target's financial adviser.

Why targets add disclosure instead of litigating

Merger disclosure suits follow a well-worn pattern. Once a proxy statement goes out, plaintiffs' firms and individual holders send demand letters arguing the document omits material facts — the timeline of negotiations, conflicts disclosures for advisers, or the inputs behind the fairness opinion. Some escalate into filed lawsuits seeking to delay or enjoin the vote.

Companies rarely test those claims in court. The cheaper path is to file a supplement on Form 8-K or as additional proxy material, restate that the original disclosure was adequate, and say the extra detail is provided voluntarily and without conceding that anything was required. That is the posture Bio-Techne has adopted. The practical effect is to strip away the argument that shareholders will vote on incomplete information — which is the argument a court would need in order to hold up a meeting.

For shareholders, the more useful consequence is that they get to see numbers that were previously summarized. Disclosure supplements typically expand on the discounted cash flow assumptions, the selected companies and precedent transactions used for comparison, and the implied per-share ranges each method produced.

What the Goldman Sachs analyses matter for

The banker's work is the reference point in any merger vote. A fairness opinion is a formal statement that the consideration on offer is fair, from a financial point of view, to the holders receiving it. It is not a recommendation to vote yes and it is not a valuation of the company in the abstract — it is a judgment on a specific price at a specific moment.

Goldman Sachs Group Inc. (NYSE: GS) provided the valuation analyses now being expanded. Where a supplement matters is in the detail beneath the opinion: what growth rates and discount rates went into the cash flow model, how the comparable-company set was chosen, and how much of the implied range sits above or below the agreed consideration. Holders weighing the deal against standalone value, and any arbitrage funds sizing a position, read those inputs closely.

Goldman shares last closed at $988.45, down 3.96% on the day, with a session range of $978.93 to $1,013.69, as of the last trade on Monday, 14 September 2026.

The shares are not behaving like a deal in doubt

Bio-Techne stock last closed at $72.27, up 0.21%, having traded in a tight $72.17 to $72.30 band. That narrowness is itself information. A stock pinned inside a few cents on a day when the broader tape was soft is a stock trading on deal arithmetic rather than on fundamentals — the classic signature of a target whose price is anchored to announced consideration and a perceived closing probability.

The wider market was lower in the same session. The S&P 500 (SPY) closed at $760.88, down 0.45%; the Nasdaq 100 (QQQ) closed at $709.18, down 0.80%; and the Dow 30 (DIA) finished at $524.49, down 0.25%. Bio-Techne's small gain against that backdrop is consistent with a name that has decoupled from index direction, as pending targets usually do once a definitive agreement is on the table.

What the price does not tell you is whether the market believes the offer is generous. That question belongs to the supplemental disclosure, and it will be settled at the ballot box.

The vote timeline is the thing to watch

Disclosure litigation almost never kills a deal. It can, however, move dates. The practical risks to the calendar are narrow:

• An injunction motion. A plaintiff can ask a court to postpone the meeting until further disclosure is made. Filing a voluntary supplement is the standard way to render that motion moot before it is heard.
• A mootness fee demand. After a supplement lands, plaintiffs' counsel typically seek fees on the theory their letters produced the added disclosure. This is a cost item, not a timing item.
• Adjournment for votes. If proxies are short of the required threshold, boards adjourn meetings to solicit more. That is a shareholder-support question, unrelated to the lawsuit.
• Regulatory clearance. A cross-border pharmaceutical and life-science tools combination carries antitrust and foreign-investment reviews that run on their own clock, independent of the vote.

For a transatlantic transaction involving Germany's Merck KGaA, the regulatory track is usually the longer pole. The shareholder vote establishes the mandate; clearances determine when the deal can actually close.

What holders should read in the supplement

Three things are worth locating in any supplemental filing of this kind. First, the background-of-the-merger section: whether other parties were contacted, whether there was a pre-signing market check, and how the price moved across rounds of negotiation. Second, the adviser's implied per-share ranges and the assumptions that drove them. Third, any disclosure of the adviser's prior relationships and fees with either side, since conflict allegations are a recurring theme in these claims.

None of that changes the economics of the transaction. It changes the confidence with which a shareholder can judge them — which, for a vote that hands control of the company to an acquirer, is the whole point of the exercise. The definitive answer arrives when the meeting is held and the tally is filed.

Key facts

• TECH last close: $72.27, +0.21% (as of 14 Sep 2026, 20:00 GMT)
• GS last close: $988.45, -3.96% (as of 14 Sep 2026, 20:00 GMT)
• Acquirer in talks: Merck KGaA
• Company action: Voluntary supplemental proxy disclosures after merger lawsuit and demand letters

Frequently asked questions

Why did Bio-Techne supplement its proxy disclosures?

Bio-Techne received a merger-related lawsuit and shareholder demand letters alleging its proxy statement lacked material detail. Rather than litigate, the company voluntarily filed additional disclosure covering its merger talks with Merck KGaA and the valuation analyses prepared by Goldman Sachs. Filing a supplement is the standard, low-cost way to remove any argument that shareholders are voting on incomplete information.

Does the lawsuit put the merger at risk?

Disclosure lawsuits of this type rarely block deals. They typically seek more information rather than damages, and a voluntary supplement usually resolves the claim before any injunction hearing. The more common consequence is a mootness fee paid to plaintiffs' counsel. Closing risk generally comes from regulatory clearances or shareholder support, not from disclosure litigation.

What is a fairness opinion?

A fairness opinion is a formal written statement from a financial adviser saying the consideration offered in a transaction is fair, from a financial point of view, to the shareholders receiving it. It is not a recommendation to vote in favor, nor a valuation of the company in isolation. It addresses one specific price at one specific moment in time.

How did Bio-Techne shares trade most recently?

Bio-Techne last closed at $72.27, up 0.21% on the day, within a very narrow range of $72.17 to $72.30, as of the last trade at 20:00 GMT on 14 September 2026. That tight band is typical of a company with a pending acquisition, where the price is anchored to deal terms rather than to day-to-day market moves.

What role does Goldman Sachs play in the deal?

Goldman Sachs provided the valuation analyses underpinning Bio-Techne's proxy disclosure on the proposed Merck KGaA transaction. Bio-Techne's supplemental filing expands on that work. Goldman shares last closed at $988.45, down 3.96%, with a session range of $978.93 to $1,013.69, as of 14 September 2026.

What should shareholders watch next?

The date and outcome of the shareholder meeting is the immediate milestone, followed by antitrust and foreign-investment clearances for a cross-border life-science transaction. Adjournments to gather additional proxies are possible if support falls short. Any further supplemental filings, and the resolution of plaintiffs' fee claims, would also appear in the company's securities filings.

Sources

• Bio-Techne (TECH) Faces Merger Lawsuit, Voluntarily Supplements Proxy Disclosures Ahead of Key ... — GuruFocus

Photo: Tima Miroshnichenko · Pexels Licence — source